Fundació Althaia
Welcome,         Profile    Billing    Logout  
 5 Trials 
35 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Fernandez, Rafael
NCT06384157: Proof of Concept and Dose-ranging Study of INDV-2000 in Individuals With Moderate to Severe Opioid Use Disorder

Recruiting
2
300
US
INDV-2000, Placebo
Indivior Inc.
Opioid Use Disorder
08/25
09/25
iinnovate-1, NCT03215030 / 2021-006038-37: A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma

Completed
1/2
272
Europe, Canada, Japan, US, RoW
Modakafusp alfa, TAK-573, TEV-48573, Dexamethasone
Takeda, Takeda Development Center Americas, Inc.
Multiple Myeloma
07/24
11/24
SleepUCI, NCT05847374: Effect of Asynchronies on Sleep Disruption During Mechanical Ventilation

Completed
N/A
50
Europe
Polysomnography, Ventilator waveforms recording
Althaia Xarxa Assistencial Universitària de Manresa
Sleep
07/22
07/22
NCT05526053: Lung Volume Preservation During Extubation

Recruiting
N/A
1644
Europe
Lung volume preservation
Althaia Xarxa Assistencial Universitària de Manresa
Weaning Failure, Pulmonary Collapse
06/24
12/24
NCT05363332: Impact and Sequelae of High Ventilatory Drive in Critically Ill COVID-19 Patients

Recruiting
N/A
126
Europe
Corporacion Parc Tauli, Althaia Xarxa Assistencial Universitària de Manresa, Hospital Universitario Central de Asturias
COVID-19, Critical Illness, Hypoxemic Respiratory Failure, Neurocognitive Dysfunction, Mechanical Ventilation Complication
05/23
11/24
Batlle, Montserrat
NCT05363332: Impact and Sequelae of High Ventilatory Drive in Critically Ill COVID-19 Patients

Recruiting
N/A
126
Europe
Corporacion Parc Tauli, Althaia Xarxa Assistencial Universitària de Manresa, Hospital Universitario Central de Asturias
COVID-19, Critical Illness, Hypoxemic Respiratory Failure, Neurocognitive Dysfunction, Mechanical Ventilation Complication
05/23
11/24
Subira, Carles CS
ROX-1, NCT04707729: ROX Index for the Timing of Intubation in Nasal High Flow

Recruiting
N/A
630
Europe, US, RoW
ROX index algorithm
Hospital Universitari Vall d'Hebron Research Institute
Acute Hypoxemic Respiratory Failure
12/24
06/25
NCT05526053: Lung Volume Preservation During Extubation

Recruiting
N/A
1644
Europe
Lung volume preservation
Althaia Xarxa Assistencial Universitària de Manresa
Weaning Failure, Pulmonary Collapse
06/24
12/24
VITA, NCT06727903: Predictive Model for Mortality in Older People With Critical Illness

Not yet recruiting
N/A
450
Europe
laboratory biomarker analysis
Consorci Sanitari de l'Alt Penedès i Garraf
Critical Illness
05/26
05/26
point, MFAR Sponsor designated contact
RADIAN, NCT05784012 / 2023-000183-65: Two-cohort Study of Niraparib and Dostarlimab Plus (Chemo)RadIotherapy in Locally-Advanced Head and Neck Squamous Cell Carcinoma

Recruiting
1/2
34
Europe
Dostarlimab, Niraparib, cisplatin plus radiotherapy
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello, GlaxoSmithKline, MFAR
Head and Neck Squamous Cell Carcinoma
09/27
03/29
Sponsor, A responsible person Designated by the
PROTINCOL, NCT05625932 / 2022-001534-11: TINzaparin Prophylaxis in Patients With Metastatic Colorectal Cancer

Recruiting
3
526
Europe
Tinzaparin, Innohep
Galician Research Group on Digestive Tumors, LEO Pharma
Colorectal Cancer Metastatic, Thromboembolism
12/24
03/25
RIALTO, NCT06878664: Randomized Interval Assessment Trial of Lu177-Dotatate in Slowly Progressive G1-2 Advanced Midgut Neuroendocrine Tumors

Not yet recruiting
3
166
Europe
177Lu-Dotatate (7.4 Gigabecquerel/cycle) during 30 min intravenous infusion every 16 weeks (q8w) x 4 cycles; 2) and 3) as in the experimental arm., 177Lu-DOTA0-Tyr 3-Octreotate, 177Lu-DOTATE, LUTATHERA, lutetium (177Lu) oxodotreotide, 177Lu-Dotatate (7.4 Gigabecquerel/cycle) during 30 min intravenous infusion every 8 weeks (q8w) x 4 cycles; 2) and 3) as in the experimental arm., Amino acid solution, Lanreotide (Autogel formulation) or Octreotide LAR
Grupo Espanol de Tumores Neuroendocrinos, Grupo Español de Tumores Neuroendocrinos y Endocrinos (GETNE)
Grade1-2 Advanced Midgut Neuroendocrine Tumors (NETs)
01/29
01/29
LEVEL, NCT05918302: Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.

Recruiting
3
120
Europe
177Lu-edotreotide, Everolimus
Grupo Espanol de Tumores Neuroendocrinos, ITM Oncologics GmbH, MFAR
Neuroendocrine Tumors, Lung Neuroendocrine Neoplasm, Thymus Neoplasms
03/28
07/28
DUTHY, NCT03753919: Durvalumab Plus Tremelimumab for the Treatment of Patients with Progressive, Refractory Advanced Thyroid Carcinoma -The Trial

Terminated
2
79
Europe
Durvalumab, MEDI4736, Tremelimumab
Grupo Espanol de Tumores Neuroendocrinos, MFAR
Metastatic Thyroid Papillary Carcinoma, Metastatic Thyroid Follicular Carcinoma, Metastatic Thyroid Cancer
11/24
11/24
SITISVEAL, NCT05542342 / 2021-002474-99: Sitravatinib and Tislelizumab in Patients With Metastatic Uveal Melanoma With Liver Metastases.

Active, not recruiting
2
16
Europe
Tislelizumab, Sitravatinib Malate
Grupo Español Multidisciplinar de Melanoma, Mirati Therapeutics Inc., BeiGene
Uveal Melanoma
12/23
08/25
NCT06538857: CEB-01 in Locally Resectable Pancreatic Cancer

Recruiting
2
21
Europe
Standard surgery, CEB-01
CEBIOTEX, MFAR
Pancreatic Carcinoma
09/28
09/28
PEMBROLA, NCT05201612: Pembrolizumab and Olaparib in Homologous-recombination Deficient (HRD) Advanced Colorectal Cancer (CRC).

Recruiting
2
40
Europe
Olaparib, Lynparza, Pembrolizumab, Keytruda
Grupo Espanol Multidisciplinario del Cancer Digestivo, Merk Sharp & Dohme España S.A.
Metastatic Colorectal Cancer
09/24
03/25
SETHY, NCT06235216: Sacituzumab govitEcan in THYroid Cancers

Recruiting
2
42
Europe
Sacituzumab govitecan, Trodelvy
Grupo Espanol de Tumores Neuroendocrinos, MFAR, Gilead Sciences
Differentiated Thyroid Cancer, Anaplastic Thyroid Cancer
12/27
12/27
VERDI, NCT06668558: Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia

Recruiting
2
29
Europe
Azacitidine (AZA), Venetoclax
Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias
Acute Myeloid Leukemia
06/28
07/28
VEXILLUM, NCT05219435 / 2021-005364-22: Study of NIVOLUMAB/IPILIMUMAB Maintenance in Unresectable Locally Advanced or Metastatic Urothelial Cancer

Recruiting
2
66
Europe
Nivolumab, Opdivo, Ipilimumab, Yervoy
Spanish Oncology Genito-Urinary Group, Bristol-Myers Squibb
Urothelial Cancer
03/25
12/25
ERBIOTAX, NCT06856213: Study of Cetuximab Plus/Minus Weekly Paclitaxel After Progression to First-Line Pembrolizumab Plus Platinum-5FU in Subjects with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck.

Not yet recruiting
2
65
Europe
Cetuximab, Paclitaxel
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
Recurrent / Metastatic Head and Neck Squamous Cell Carcinoma
10/28
10/28
ENCEFALO, NCT06887088: Encorafenib and biNimetinib Followed by CEmiplimab and FiAnLimab in Patients With BRAF Mutant melanOma and Symptomatic Brain Metastases

Not yet recruiting
2
33
Europe
Encorafenib + Binimetinib, cemiplimab+fianlimab
Grupo Español Multidisciplinar de Melanoma, Regeneron Pharmaceuticals, MFAR, Pierre Fabre Laboratories
Melanoma BRAF V600E/K Mutated, Melanoma and Brain Metastases
01/28
01/28
CABOTHYROID, NCT05660954: Cabozantinib In Advanced Radioactive-Iodine Refractory Differentiated Thyroid Cancer.

Active, not recruiting
2
41
Europe
Cabozantinib
Grupo Espanol de Tumores Neuroendocrinos, Ipsen, MFAR
Differentiated Thyroid Cancer
06/25
06/25
PlugIN, NCT06906822: PLUG-IN: Pembrolizumab Combined With Enfortumab Vedotin for Advanced Melanoma Patients

Not yet recruiting
2
60
Europe
enfortumab vedotin, pembrolizumab
Grupo Español Multidisciplinar de Melanoma, Merck Sharp & Dohme LLC, Astellas Pharma Inc
Melanoma
06/27
06/28
TIRANUS, NCT05661188: Tiraglolumab Atezolizumab and Chemoradiotherapy in Localized Anal Carcinoma

Recruiting
2
45
Europe
Atezolizumab plus Tiraglolumab
Grupo Espanol Multidisciplinario del Cancer Digestivo, Hoffmann-La Roche
Squamous Cell Carcinoma of the Anal Canal
06/27
06/28
CAN-201 NDG, NCT05635734 / 2022-002801-36: Azeliragon and Chemoradiotherapy in Newly Diagnosed Glioblastoma

Active, not recruiting
1/2
18
Europe
Azeliragon 5 mg, Azeliragon 10 mg, Azeliragon 20 mg
Cantex Pharmaceuticals, Cantex Pharmaceuticals Inc.
Glioblastoma
12/24
12/25
AFAN, NCT06648096: Afatinib in Patients with Fanconi Anemia (FA) and Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)

Not yet recruiting
1/2
25
Europe
Afatinib
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau, MFAR Clinical Research S.L.
Fanconi Anemia, Head and Neck Squamous Cell Carcinoma
12/28
12/28
CEB-01-RLS01-CT, NCT04619056: First-in-man Clinical Trial of CEB-01 PLGA Membrane in Recurrent or Locally Advanced Retroperitoneal Soft Tissue Sarcoma

Active, not recruiting
1
21
Europe
CEB-01 membrane loaded with SN-38
CEBIOTEX
Locally Advanced Soft Tissue Sarcoma, Recurrent Soft Tissue Sarcoma
05/25
05/25
MOLTHY, NCT04970134: Spanish Study for Molecular Characterization of Thyroid Carcinoma

Active, not recruiting
N/A
150
Europe
Immunohistochemistry (IHC), Fluorescence In-Situ Hybridization (FISH), Oncomine Focus Assay Platform with 52 genes, Next Generation Sequencing (NGS)
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
Differentiated Thyroid Carcinoma, Medullary Thyroid Carcinoma
01/23
03/25
NUTRIGETNE, NCT04986085: Nutrition in Gastroenteropancreatic Neuroendocrine Tumor

Completed
N/A
399
Europe
Grupo Espanol de Tumores Neuroendocrinos
Gastroenteropancreatic Neuroendocrine Tumor
01/24
02/24
REGETNE-Tiroides, NCT03765333: GETNE Registration of Thyroid Cancer

Recruiting
N/A
20
Europe
Grupo Espanol de Tumores Neuroendocrinos
Thyroid Cancer
12/25
12/25
TESEO, NCT03855592: Registry of Thrombosis & NEoplasia of "Sociedad Española de Oncología Médica"

Recruiting
N/A
700
Europe
Fundación Sociedad Española de Oncologia Médica
Thromboembolism, Cancer
07/24
07/24
SOGUG-PRINCIS, NCT06724159: Observational Study of the Effectiveness of Funded Drugs for Genitourinary Tumors.

Recruiting
N/A
500
Europe
darolutamide, Nivolumab monotherapy, enfortumab vedotin
Spanish Oncology Genito-Urinary Group, MFAR
Genitourinary Cancers
12/27
12/27
SPAINTRK, NCT06837090: Retrospective Analysis of the Experience With Larotrectinib in Patients With Solid Neoplasms With NTRK Fusion in Spain

Recruiting
N/A
19
Europe
Grupo Espanol de Tumores Neuroendocrinos, MFAR, Grupo Español de Tumores Neuroendocrinos y Endocrinos (GETNE)
Solid Neoplasms With NTRK Fusions
12/25
01/26
REPTT, NCT05914441: Spanish-Portuguese Thrombotic Thrombocytopenic Purpura Registry

Recruiting
N/A
300
Europe
Standard clinical practice
Fundación Española de Hematología y Hemoterapía
Purpura, Thrombocytopenic
09/26
12/26
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Fernandez, Rafael
NCT06384157: Proof of Concept and Dose-ranging Study of INDV-2000 in Individuals With Moderate to Severe Opioid Use Disorder

Recruiting
2
300
US
INDV-2000, Placebo
Indivior Inc.
Opioid Use Disorder
08/25
09/25
iinnovate-1, NCT03215030 / 2021-006038-37: A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma

Completed
1/2
272
Europe, Canada, Japan, US, RoW
Modakafusp alfa, TAK-573, TEV-48573, Dexamethasone
Takeda, Takeda Development Center Americas, Inc.
Multiple Myeloma
07/24
11/24
SleepUCI, NCT05847374: Effect of Asynchronies on Sleep Disruption During Mechanical Ventilation

Completed
N/A
50
Europe
Polysomnography, Ventilator waveforms recording
Althaia Xarxa Assistencial Universitària de Manresa
Sleep
07/22
07/22
NCT05526053: Lung Volume Preservation During Extubation

Recruiting
N/A
1644
Europe
Lung volume preservation
Althaia Xarxa Assistencial Universitària de Manresa
Weaning Failure, Pulmonary Collapse
06/24
12/24
NCT05363332: Impact and Sequelae of High Ventilatory Drive in Critically Ill COVID-19 Patients

Recruiting
N/A
126
Europe
Corporacion Parc Tauli, Althaia Xarxa Assistencial Universitària de Manresa, Hospital Universitario Central de Asturias
COVID-19, Critical Illness, Hypoxemic Respiratory Failure, Neurocognitive Dysfunction, Mechanical Ventilation Complication
05/23
11/24
Batlle, Montserrat
NCT05363332: Impact and Sequelae of High Ventilatory Drive in Critically Ill COVID-19 Patients

Recruiting
N/A
126
Europe
Corporacion Parc Tauli, Althaia Xarxa Assistencial Universitària de Manresa, Hospital Universitario Central de Asturias
COVID-19, Critical Illness, Hypoxemic Respiratory Failure, Neurocognitive Dysfunction, Mechanical Ventilation Complication
05/23
11/24
Subira, Carles CS
ROX-1, NCT04707729: ROX Index for the Timing of Intubation in Nasal High Flow

Recruiting
N/A
630
Europe, US, RoW
ROX index algorithm
Hospital Universitari Vall d'Hebron Research Institute
Acute Hypoxemic Respiratory Failure
12/24
06/25
NCT05526053: Lung Volume Preservation During Extubation

Recruiting
N/A
1644
Europe
Lung volume preservation
Althaia Xarxa Assistencial Universitària de Manresa
Weaning Failure, Pulmonary Collapse
06/24
12/24
VITA, NCT06727903: Predictive Model for Mortality in Older People With Critical Illness

Not yet recruiting
N/A
450
Europe
laboratory biomarker analysis
Consorci Sanitari de l'Alt Penedès i Garraf
Critical Illness
05/26
05/26
point, MFAR Sponsor designated contact
RADIAN, NCT05784012 / 2023-000183-65: Two-cohort Study of Niraparib and Dostarlimab Plus (Chemo)RadIotherapy in Locally-Advanced Head and Neck Squamous Cell Carcinoma

Recruiting
1/2
34
Europe
Dostarlimab, Niraparib, cisplatin plus radiotherapy
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello, GlaxoSmithKline, MFAR
Head and Neck Squamous Cell Carcinoma
09/27
03/29
Sponsor, A responsible person Designated by the
PROTINCOL, NCT05625932 / 2022-001534-11: TINzaparin Prophylaxis in Patients With Metastatic Colorectal Cancer

Recruiting
3
526
Europe
Tinzaparin, Innohep
Galician Research Group on Digestive Tumors, LEO Pharma
Colorectal Cancer Metastatic, Thromboembolism
12/24
03/25
RIALTO, NCT06878664: Randomized Interval Assessment Trial of Lu177-Dotatate in Slowly Progressive G1-2 Advanced Midgut Neuroendocrine Tumors

Not yet recruiting
3
166
Europe
177Lu-Dotatate (7.4 Gigabecquerel/cycle) during 30 min intravenous infusion every 16 weeks (q8w) x 4 cycles; 2) and 3) as in the experimental arm., 177Lu-DOTA0-Tyr 3-Octreotate, 177Lu-DOTATE, LUTATHERA, lutetium (177Lu) oxodotreotide, 177Lu-Dotatate (7.4 Gigabecquerel/cycle) during 30 min intravenous infusion every 8 weeks (q8w) x 4 cycles; 2) and 3) as in the experimental arm., Amino acid solution, Lanreotide (Autogel formulation) or Octreotide LAR
Grupo Espanol de Tumores Neuroendocrinos, Grupo Español de Tumores Neuroendocrinos y Endocrinos (GETNE)
Grade1-2 Advanced Midgut Neuroendocrine Tumors (NETs)
01/29
01/29
LEVEL, NCT05918302: Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.

Recruiting
3
120
Europe
177Lu-edotreotide, Everolimus
Grupo Espanol de Tumores Neuroendocrinos, ITM Oncologics GmbH, MFAR
Neuroendocrine Tumors, Lung Neuroendocrine Neoplasm, Thymus Neoplasms
03/28
07/28
DUTHY, NCT03753919: Durvalumab Plus Tremelimumab for the Treatment of Patients with Progressive, Refractory Advanced Thyroid Carcinoma -The Trial

Terminated
2
79
Europe
Durvalumab, MEDI4736, Tremelimumab
Grupo Espanol de Tumores Neuroendocrinos, MFAR
Metastatic Thyroid Papillary Carcinoma, Metastatic Thyroid Follicular Carcinoma, Metastatic Thyroid Cancer
11/24
11/24
SITISVEAL, NCT05542342 / 2021-002474-99: Sitravatinib and Tislelizumab in Patients With Metastatic Uveal Melanoma With Liver Metastases.

Active, not recruiting
2
16
Europe
Tislelizumab, Sitravatinib Malate
Grupo Español Multidisciplinar de Melanoma, Mirati Therapeutics Inc., BeiGene
Uveal Melanoma
12/23
08/25
NCT06538857: CEB-01 in Locally Resectable Pancreatic Cancer

Recruiting
2
21
Europe
Standard surgery, CEB-01
CEBIOTEX, MFAR
Pancreatic Carcinoma
09/28
09/28
PEMBROLA, NCT05201612: Pembrolizumab and Olaparib in Homologous-recombination Deficient (HRD) Advanced Colorectal Cancer (CRC).

Recruiting
2
40
Europe
Olaparib, Lynparza, Pembrolizumab, Keytruda
Grupo Espanol Multidisciplinario del Cancer Digestivo, Merk Sharp & Dohme España S.A.
Metastatic Colorectal Cancer
09/24
03/25
SETHY, NCT06235216: Sacituzumab govitEcan in THYroid Cancers

Recruiting
2
42
Europe
Sacituzumab govitecan, Trodelvy
Grupo Espanol de Tumores Neuroendocrinos, MFAR, Gilead Sciences
Differentiated Thyroid Cancer, Anaplastic Thyroid Cancer
12/27
12/27
VERDI, NCT06668558: Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia

Recruiting
2
29
Europe
Azacitidine (AZA), Venetoclax
Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias
Acute Myeloid Leukemia
06/28
07/28
VEXILLUM, NCT05219435 / 2021-005364-22: Study of NIVOLUMAB/IPILIMUMAB Maintenance in Unresectable Locally Advanced or Metastatic Urothelial Cancer

Recruiting
2
66
Europe
Nivolumab, Opdivo, Ipilimumab, Yervoy
Spanish Oncology Genito-Urinary Group, Bristol-Myers Squibb
Urothelial Cancer
03/25
12/25
ERBIOTAX, NCT06856213: Study of Cetuximab Plus/Minus Weekly Paclitaxel After Progression to First-Line Pembrolizumab Plus Platinum-5FU in Subjects with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck.

Not yet recruiting
2
65
Europe
Cetuximab, Paclitaxel
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
Recurrent / Metastatic Head and Neck Squamous Cell Carcinoma
10/28
10/28
ENCEFALO, NCT06887088: Encorafenib and biNimetinib Followed by CEmiplimab and FiAnLimab in Patients With BRAF Mutant melanOma and Symptomatic Brain Metastases

Not yet recruiting
2
33
Europe
Encorafenib + Binimetinib, cemiplimab+fianlimab
Grupo Español Multidisciplinar de Melanoma, Regeneron Pharmaceuticals, MFAR, Pierre Fabre Laboratories
Melanoma BRAF V600E/K Mutated, Melanoma and Brain Metastases
01/28
01/28
CABOTHYROID, NCT05660954: Cabozantinib In Advanced Radioactive-Iodine Refractory Differentiated Thyroid Cancer.

Active, not recruiting
2
41
Europe
Cabozantinib
Grupo Espanol de Tumores Neuroendocrinos, Ipsen, MFAR
Differentiated Thyroid Cancer
06/25
06/25
PlugIN, NCT06906822: PLUG-IN: Pembrolizumab Combined With Enfortumab Vedotin for Advanced Melanoma Patients

Not yet recruiting
2
60
Europe
enfortumab vedotin, pembrolizumab
Grupo Español Multidisciplinar de Melanoma, Merck Sharp & Dohme LLC, Astellas Pharma Inc
Melanoma
06/27
06/28
TIRANUS, NCT05661188: Tiraglolumab Atezolizumab and Chemoradiotherapy in Localized Anal Carcinoma

Recruiting
2
45
Europe
Atezolizumab plus Tiraglolumab
Grupo Espanol Multidisciplinario del Cancer Digestivo, Hoffmann-La Roche
Squamous Cell Carcinoma of the Anal Canal
06/27
06/28
CAN-201 NDG, NCT05635734 / 2022-002801-36: Azeliragon and Chemoradiotherapy in Newly Diagnosed Glioblastoma

Active, not recruiting
1/2
18
Europe
Azeliragon 5 mg, Azeliragon 10 mg, Azeliragon 20 mg
Cantex Pharmaceuticals, Cantex Pharmaceuticals Inc.
Glioblastoma
12/24
12/25
AFAN, NCT06648096: Afatinib in Patients with Fanconi Anemia (FA) and Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)

Not yet recruiting
1/2
25
Europe
Afatinib
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau, MFAR Clinical Research S.L.
Fanconi Anemia, Head and Neck Squamous Cell Carcinoma
12/28
12/28
CEB-01-RLS01-CT, NCT04619056: First-in-man Clinical Trial of CEB-01 PLGA Membrane in Recurrent or Locally Advanced Retroperitoneal Soft Tissue Sarcoma

Active, not recruiting
1
21
Europe
CEB-01 membrane loaded with SN-38
CEBIOTEX
Locally Advanced Soft Tissue Sarcoma, Recurrent Soft Tissue Sarcoma
05/25
05/25
MOLTHY, NCT04970134: Spanish Study for Molecular Characterization of Thyroid Carcinoma

Active, not recruiting
N/A
150
Europe
Immunohistochemistry (IHC), Fluorescence In-Situ Hybridization (FISH), Oncomine Focus Assay Platform with 52 genes, Next Generation Sequencing (NGS)
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
Differentiated Thyroid Carcinoma, Medullary Thyroid Carcinoma
01/23
03/25
NUTRIGETNE, NCT04986085: Nutrition in Gastroenteropancreatic Neuroendocrine Tumor

Completed
N/A
399
Europe
Grupo Espanol de Tumores Neuroendocrinos
Gastroenteropancreatic Neuroendocrine Tumor
01/24
02/24
REGETNE-Tiroides, NCT03765333: GETNE Registration of Thyroid Cancer

Recruiting
N/A
20
Europe
Grupo Espanol de Tumores Neuroendocrinos
Thyroid Cancer
12/25
12/25
TESEO, NCT03855592: Registry of Thrombosis & NEoplasia of "Sociedad Española de Oncología Médica"

Recruiting
N/A
700
Europe
Fundación Sociedad Española de Oncologia Médica
Thromboembolism, Cancer
07/24
07/24
SOGUG-PRINCIS, NCT06724159: Observational Study of the Effectiveness of Funded Drugs for Genitourinary Tumors.

Recruiting
N/A
500
Europe
darolutamide, Nivolumab monotherapy, enfortumab vedotin
Spanish Oncology Genito-Urinary Group, MFAR
Genitourinary Cancers
12/27
12/27
SPAINTRK, NCT06837090: Retrospective Analysis of the Experience With Larotrectinib in Patients With Solid Neoplasms With NTRK Fusion in Spain

Recruiting
N/A
19
Europe
Grupo Espanol de Tumores Neuroendocrinos, MFAR, Grupo Español de Tumores Neuroendocrinos y Endocrinos (GETNE)
Solid Neoplasms With NTRK Fusions
12/25
01/26
REPTT, NCT05914441: Spanish-Portuguese Thrombotic Thrombocytopenic Purpura Registry

Recruiting
N/A
300
Europe
Standard clinical practice
Fundación Española de Hematología y Hemoterapía
Purpura, Thrombocytopenic
09/26
12/26

Download Options